pre-IPO PHARMA

COMPANY OVERVIEW

BioAxone is committed to applying a deep understanding of axon regeneration and neuronal signaling pathways to transform the lives of patients afflicted with neurotrauma or neurovascular disorders.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Neurological DIsorders

  • WEBSITE

    https://bioaxonebio.com/


    CAREER WEBSITE

    https://bioaxonebio.com/contact-us/careers/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Jun 22, 2022

    BioAxone BioSciences Announces Patent Issued for Pharmaceutical Compositions of BA-210, a Rho Inhibitor for the Treatment of Spinal Cord Injury


    Jun 21, 2021

    BioAxone BioSciences Announces License of Cerebral Cavernous Malformations Drug Candidate BA-1049 and Portfolio of Rho Kinase Inhibitors to Neurelis


    Jun 8, 2021

    BioAxone BioSciences Announces Notice of Allowance for Self-Delivering RNA Interference for the Treatment of Spinal Cord Injury


    Aug 28, 2020

    BioAxone BioSciences Announces Notice of Allowance that Expands Scope of Key ROCK Inhibitors for Treatment of Cerebral Aneurysms


    Dec 16, 2019

    CORRECTING and REPLACING BioAxone BioSciences Expands Patent for Treatment of Cerebral Cavernous Malformations and Cerebral Aneurysms with Rho Kinase Inhibitors


    For More Press Releases


    Google Analytics Alternative